P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes (2017)
- Autores:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1161/CIR.0000000000000546
- Assuntos: SÍNDROME CORONARIANA AGUDA; PLAQUETAS SANGUÍNEAS; CONDUTAS TERAPÊUTICAS
- Idioma: Inglês
- Imprenta:
- Fonte:
- Título do periódico: Circulation
- ISSN: 0009-7322
- Volume/Número/Paginação/Ano: v. 136, n. 24, p. e458-e459, 2017
- Nome do evento: 2017 AHA Late-Breaking Sciences Abstracts
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
ROE, Matthew T et al. P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes. Circulation. Dallas: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1161/CIR.0000000000000546. Acesso em: 23 abr. 2024. , 2017 -
APA
Roe, M. T., Ohman, E. M., Povsic, T. J., White, J., Rockold, F., Montalescot, G., et al. (2017). P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes. Circulation. Dallas: Faculdade de Medicina, Universidade de São Paulo. doi:10.1161/CIR.0000000000000546 -
NLM
Roe MT, Ohman EM, Povsic TJ, White J, Rockold F, Montalescot G, Cornel JH, Nicolau JC, Steg PG, Gibson CM. P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes [Internet]. Circulation. 2017 ; 136( 24): e458-e459.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1161/CIR.0000000000000546 -
Vancouver
Roe MT, Ohman EM, Povsic TJ, White J, Rockold F, Montalescot G, Cornel JH, Nicolau JC, Steg PG, Gibson CM. P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes [Internet]. Circulation. 2017 ; 136( 24): e458-e459.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1161/CIR.0000000000000546 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.1161/CIR.0000000000000546 (Fonte: oaDOI API)
Como citar
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
